ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
“We are driven to improve the lives of people with Parkinson’s disease
psychosis and their caregivers,” said
In addition to continued support for the
- Moving Day® walks hosted by Parkinson’s Foundation across the country give people with Parkinson’s and their families the opportunity to amplify their voice and raise money to increase awareness and understanding of Parkinson’s disease.
Walks hosted by the American Parkinson’s
Disease Associationacross the country aim to turn the Parkinson’s community’s passion and concern about Parkinson’s into a positive experience that raises awareness of the disease.
Davis Phinney Foundationfor Parkinson’s Victory Summit® in Austinon April 13is a national education and inspiration event, offering in-person and virtual access to dynamic presentations from leading movement disorder neurologists and therapists from across the country.
Foundation Centers for Excellence Leadership Conferencehosted 45 Parkinson’s centers to discuss in-network updates, cutting edge research, and the latest Parkinson’s topics to foster new ideas and collaboration among Parkinson’s clinicians, scientists, and researchers.
Association of San Diego Stepby Step 5K Walk on April 7included ACADIA employees helping raise funds to support critical resources for the estimated 60,000 people affected by Parkinson’s disease in San Diego Countywhere ACADIA is headquartered.
"Moving Day walks are a critical component of the Parkinson’s
Foundation’s efforts to raise money and help improve life for people
affected by Parkinson’s disease," said
About Parkinson’s Disease and Parkinson’s Disease Psychosis
Parkinson’s disease is a progressive nervous system disorder. About one million people in
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.
Important Safety Information and Indication for NUPLAZID (pimavanserin)
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for reduced efficacy and an increase in NUPLAZID dosage may be needed.
Pediatric Use: Safety and efficacy have not been established in pediatric patients.
Dosage and Administration: Recommended dose: 34 mg taken orally once daily, without titration.
Indication: NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
You are encouraged to report negative side effects of prescription drugs
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please see the full Prescribing Information including Boxed WARNING for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
ACADIA Pharmaceuticals Inc.
Mark Johnson, CFA
ACADIA Pharmaceuticals Inc.